NeoGenomics Competitors
| NEO Stock | USD 12.50 0.19 1.54% |
NeoGenomics vs Alpha Teknova Correlation
Excellent diversification
The correlation between NeoGenomics and TKNO is -0.56 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding NeoGenomics and TKNO in the same portfolio, assuming nothing else is changed.
Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.66 | SPI | Spire Healthcare | PairCorr |
| 0.64 | S00 | Spire Healthcare | PairCorr |
| 0.57 | FMS | Fresenius Medical Care | PairCorr |
| 0.47 | REG | Regis Healthcare | PairCorr |
| 0.46 | UHS | Universal Health Services | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeoGenomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NeoGenomics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between NeoGenomics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of NeoGenomics and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of NeoGenomics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between NeoGenomics Stock performing well and NeoGenomics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze NeoGenomics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| XGN | 2.66 | (1.69) | 0.00 | 31.47 | 0.00 | 3.11 | 17.46 | |||
| MDXH | 2.83 | (0.51) | 0.00 | (0.25) | 0.00 | 6.96 | 17.05 | |||
| STXS | 2.75 | (0.45) | 0.00 | (0.30) | 0.00 | 4.69 | 18.81 | |||
| ACRS | 4.54 | 1.06 | 0.16 | (0.28) | 4.62 | 8.62 | 84.20 | |||
| QTRX | 3.32 | 0.34 | 0.11 | 0.21 | 3.25 | 8.16 | 34.06 | |||
| SGMT | 3.21 | (0.29) | 0.00 | (1.05) | 0.00 | 6.08 | 23.02 | |||
| SMTI | 2.88 | (0.55) | 0.00 | (0.23) | 0.00 | 5.60 | 26.42 | |||
| ARCT | 3.04 | (0.39) | 0.00 | (0.24) | 0.00 | 6.10 | 15.98 | |||
| HUMA | 3.75 | (0.81) | 0.00 | (0.31) | 0.00 | 8.16 | 20.54 | |||
| TKNO | 3.06 | (1.17) | 0.00 | (1.09) | 0.00 | 4.75 | 23.61 |
Cross Equities Net Income Analysis
Compare NeoGenomics and related stocks such as Exagen Inc, MDxHealth SA ADR, and Stereotaxis Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XGN | (7.3 M) | (7.3 M) | (7.3 M) | (13.5 M) | (15 M) | (19.2 M) | (25.6 M) | (25.6 M) | (8 M) | (12 M) | (16.7 M) | (26.9 M) | (47.4 M) | (23.7 M) | (15.1 M) | (13.6 M) | (14.3 M) |
| MDXH | (7 M) | (9 M) | (11.9 M) | (16.2 M) | (15.3 M) | (14.5 M) | (13.2 M) | (12.3 M) | (32.5 M) | (43.1 M) | (28.7 M) | (29 M) | (44 M) | (43.1 M) | (38.1 M) | (34.3 M) | (32.5 M) |
| STXS | (9.5 M) | (32 M) | (9.2 M) | (68.8 M) | (5.2 M) | (7.4 M) | (5.3 M) | (5.9 M) | 116.8 K | (4.2 M) | (6.5 M) | (10.7 M) | (19.2 M) | (20.7 M) | (24 M) | (27.7 M) | (29 M) |
| ACRS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (8.5 M) | (20.6 M) | (48.1 M) | (68.5 M) | (132.7 M) | (161.4 M) | (51.2 M) | (90.9 M) | (86.9 M) | (88.5 M) | (132.1 M) | (118.9 M) | (124.8 M) |
| QTRX | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (23.2 M) | (27 M) | (31 M) | (40.8 M) | (31.5 M) | (57.7 M) | (99.6 M) | (28.4 M) | (38.5 M) | (34.7 M) | (36.4 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (27.9 M) | (45.6 M) | (41 M) | (43.1 M) |
| SMTI | 477.6 K | (12.7 M) | (1.8 M) | (4.1 M) | (2.3 M) | (1.3 M) | (415.7 K) | 331.3 K | (600.6 K) | (2.8 M) | (4.4 M) | (7.9 M) | (7.9 M) | (4.3 M) | (9.7 M) | (8.7 M) | (8.3 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
| TKNO | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 3.6 M | (9.8 M) | (47.5 M) | (36.8 M) | (26.7 M) | (24.1 M) | (25.3 M) |
NeoGenomics and related stocks such as Exagen Inc, MDxHealth SA ADR, and Stereotaxis Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in NeoGenomics financial statement analysis. It represents the amount of money remaining after all of NeoGenomics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.NeoGenomics Competitive Analysis
The better you understand NeoGenomics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, NeoGenomics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across NeoGenomics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
NeoGenomics Competition Performance Charts
Five steps to successful analysis of NeoGenomics Competition
NeoGenomics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by NeoGenomics in relation to its competition. NeoGenomics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of NeoGenomics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact NeoGenomics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to NeoGenomics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your NeoGenomics position
In addition to having NeoGenomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out NeoGenomics Correlation with its peers. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.